Almost 2 years ago there was a Trading Halt and CR (29/07/2016)

When the Trading Halt was announced, the share price was $0.45.  The main thread is here - https://hotcopper.com.au/threads/ann-capital-raise-announcement-ahz-ax.2824116/#.W1UYv9gzYk8

And the investor presentation was released, the share price was $0.37 which you can view here - https://hotcopper.com.au/threads/ann-investor-presentation-ahz-ax.2824117/#.W1UY9NgzYk8

AHZ Market Data as at 26/7/16
No. of Shares on Issue 197M
Share price $0.45
Market Cap: $88M
Cash at 30/06/16 $8.8M

AHZ Market Data as at 23/7/18 (today)
No. of Shares on Issue 284M
Share price $0.245
Market Cap: $69.58M
Cash at 30/06/16 ~$10M

We now 44.16% more shares after 2 rounds of dilution

And a share price that is down 45.55% after 2 years of toil and despair.  I do appreciate that 2 months ago we were up near the 40c mark, but this also means most of the damage was done in the last 55 days or so.

2 years ago we were also awaiting the results of the HSV-2 trials, and although "they were about safety", they weren't really and most of the value and investment on this has been lost.  The proposed partnership for AI, I believe, is more around the platform developed by Prof Frazer and team.  Retaining ~30% of this business is probably the best we could have hoped for, but this will be diluted down, or maybe completely sold of if our partners achieve their objective of listing - for which there is no guarantee of success.

2 years ago we targeting 16.04 (4th quarter) ADAPT sales of $1.6m.  Within a week we are expecting no less than $4m.  WP has stated and re-iterated $4.4m, there has been talk of "I'll be happy with $3m", but if this were the case, we would be looking at a miss of guidance by 31.8% - which I feel would have justified a forecast update to the ASX.  It's $4.4m or bust as far as I'm concerned.

2 years ago we were talking about an ADAPT pipeline consisting of DURA MATER REPAIR, WHOLE VESSELS, STEM CELL, ABDOMINAL. TAVR has been the primary focus, but I am keen to see and understand progress on these "products".  How has adoption for Dura Mater been for example?  Did we under perform, meet, or out perform our forecasts?

2 years ago we had a forecast of $14m for 2017.  Are we likely to beat this with the disruption to the infusion business earlier in the year?  A lot is riding on this quarterly as the infusion business has been what has kept our CR count to 2 in 2 years.

2 years ago we had a fairly stable list of Top 20 Shareholders.  To say it has been a bit of a bloodbath would not be an understatement with the recent announcements and actions from Minderoo, MC and Ratty. Others have bought in, but the questions remain around their commitment to the company.

Not many more sleeps, let's see where we end up come quarterly.